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Introduction: Radiotherapy is a standard treatment for prostate cancer, and image-guided radiotherapy is increasingly
being used to aid precision of dose delivery to targeted tissues. However, precision during radiotherapy cannot be
maintained when unexpected intrafraction organ motion occurs.
Case presentation: We report our experience of internal organ motion caused by persistent gas production in a
patient taking an alpha-glucosidase inhibitor. A 68-year-old Japanese man with prostate cancer visited our institution
for treatment with helical tomotherapy. He suffered from diabetes mellitus and took an alpha-glucosidase inhibitor.
Routine treatment planning computed tomography showed a large volume of rectal gas; an enema was given to void
the rectum. Subsequent treatment planning computed tomography again showed a large volume of gas. After exercise
(walking) to remove the intestinal gas, a third scan was performed as a test scan without tight fixation, which showed a
sufficiently empty rectum for planning. However, after only a few minutes, treatment planning computed tomography
again showed extreme accumulation of gas. Therefore, we postponed treatment planning computed tomography and
consulted his doctor to suspend the alpha-glucosidase inhibitor, which was the expected cause of his persistent gas.
Four days after the alpha-glucosidase inhibitor regimen was suspended, we took a fourth treatment planning computed
tomography and made a treatment plan without gas accumulation. Thereafter, the absence of rectal gas accumulation
was confirmed using daily megavolt computed tomography before treatment, and the patient received 37 fractions of
intensity-modified radiotherapy at 74Gy without rectal gas complications. In this case study, the alpha-glucosidase inhibitor
induced the accumulation of intestinal gas, which may have caused unexpected organ motion, untoward reactions, and
insufficient doses to clinical targets.
Conclusions: We suggest that patients who are taking an alpha-glucosidase inhibitor for diabetes should discontinue use
of that particular medicine prior to beginning radiotherapy.
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Prostate cancer has become one of the most pronounced
cancers among Western men, and radiotherapy plays an
important role in its treatment. To achieve optimal
outcomes without elevated toxicity, organ motion is an
important consideration during radiotherapy [1]. If a tumor
moves out of the irradiated field, local control rates de-
crease and adverse events simultaneously increase. There-
fore, numerous efforts have been made to limit organ
motion [2,3]. We installed helical tomotherapy (HT;
TomoTherapy Inc., Madison, WI, USA), which allows the
delivery of image-guided, intensity-modulated radiotherapy
(IMRT), thereby providing both accuracy and precision.
This technique avoids risks to the organs while precisely
irradiating the planning target volume, and the setup error
is reduced using routine megavolt computed tomography
(MVCT) prior to treatment.
Acarbose is an alpha-glucosidase inhibitor (AGI) that
has been approved for the treatment of type 2 diabetes
mellitus (DM) [4,5]. Acarbose inhibits carbohydrate di-
gestion, allowing excessive volumes of undigested carbo-
hydrate to reach the colon. Bacterial fermentation of this
carbohydrate produces intestinal gas, which can cause
flatulence, abdominal pain, and unintended organ mo-
tion. We report our experience with a patient who took
an AGI and developed excessive intestinal gas, whichA First 
TPCT
B 1 hour, second TPCT
C Test scan
E Four days after 
AGI suspended
D Third TPCT
Figure 1 Abdominal computed tomography images. (A) Excessive gas
images (the first scan). (B) After we gave him an enema, his rectum filled w
empty. (D) A few minutes later, the treatment planning computed tomogr
days after cessation of the alpha-glucosidase inhibitor. TPCT, treatment planresulted in prohibitive target movement. To the best of
our knowledge, this is the first report of the potential
radiotherapeutic risks of AGI-induced intestinal gas
production.
Case presentation
A 68-year-old Japanese man presented to the urological
outpatient department with high serum prostate-specific
antigen levels (62.1ng/ml). Prostate biopsies revealed
prostate cancer, with a Union for International Cancer
Control (UICC) TNM classification and Gleason Score
of cT2bN0M0 and 4+3, respectively. Our patient had
had an acute myocardial infarction at 53 years of age; he
had suffered from DM for 20 years, and he took insulin,
metformin, famotidine, aspirin, ticlopidine hydrochloride,
rosuvastatin calcium, and acarbose as medications. After
neoadjuvant hormone therapy, he received IMRT using
tomotherapy. One hour before treatment planning com-
puted tomography (TPCT) using Aquilion 64 (Toshiba
Medical Systems Corp., Tokyo, Japan), patients are
instructed to empty their rectum but not their bladder. At
the first TPCT scan, our patient’s rectum contained a large
volume of gas (Figure 1A). Therefore, we conducted an
enema and after saving urine again for approximately 1
hour, a second TPCT scan was performed (Figure 1B). Al-
though enemas usually help void rectal gas, the secondproduction on initial treatment planning computed tomography
ith gas (the second scan). (C) A test scan to confirm that his rectum is
aphy scan (the third) shows that more gas has accumulated. (E) Four
ning computed tomography; AGI, alpha-glucosidase inhibitor.
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was advised, and rectum emptying was confirmed using a
test CT scan (Figure 1C) prior to the third TPCT. Surpris-
ingly, after only a few minutes, the third TPCT scan again
showed rapid gas accumulation (Figure 1D). Thus, TPCT
was postponed because of a high risk of exceptional intra-
fractional motion. Finally, we gave up taking TPCT that
day. After consulting our patient’s doctor, his AGI regimen
was suspended on the suspicion that it caused persistent
gas accumulation. Four days later, his rectum function
was normal (Figure 1E), only minimal intestinal gas was
confirmed by daily MVCT, and 37 fractional IMRT were
performed at 74Gy without gas incident.
Discussion
Rectal gas is an important issue during radiotherapy for
prostate cancer. A distended rectum significantly de-
creases local control because of systematic differences
between planned and actual positions of the prostate
during treatment and imprecision of tissue targeting
[6,7]. Acarbose is an oral AGI that is used with diet and
exercise programs to control high blood sugar in indi-
viduals with type 2 DM. Acarbose works by slowing the
breakdown of starch (carbohydrates) from food into
sugar, thereby inhibiting an increase in blood sugar
levels after meals [4,5]. However, AGI leads to excessive
gas production by bacterial fermentation of excessive
undigested food in the gastrointestinal tract. The degree
of gas production varies among patients. However, in
this case, we observed dynamic rectal motions within
minutes and attributed these to the influence of the
AGI. During HT, adjustments for geometrical deviations
of the prostate are achieved by moving the patient’s body
and by confirming vacancy of the rectum before each
session of radiotherapy. However, unintended abrupt
rectal gas expansions result in insufficient doses to pros-
tatic tumors and overexposure to normal rectal tissue,
particularly the rectum, resulting in treatment failure
and rectal bleeding.
Several authors have reported higher risks of late rec-
tal toxicity in patients with DM [8-13]. DM causes dam-
age to the microvasculature by inducing endothelial and
vascular smooth muscle dysfunction [9]. The resulting
delayed complications are related to ischemic injury and
ulceration, owing to the loss of endothelial cell function
and reduced proliferation of arterial and venous intima.
Therefore, radiation-induced damage is prevalent in
patients with DM. In addition, we suggest that AGI ther-
apy results in enormous rectal gas accumulation, which
elevates the risk of radiotherapy failure due to dynamic
organ motion. Previously, this may have been overlooked
because relatively few patients with DM take an AGI.
Nonetheless, the use of AGIs should be monitored in
patients with DM. In some institutes, CT scans areconducted only once for treatment planning and position-
ing because of limited time for linacgraphy. However,
single CT scans neglect changes in rectal gas volumes that
can cause migration of the prostate after planning. This
case warrants further detailed studies of such risks using
data from multiple institutions and a larger number of
patients.
Conclusions
AGIs can cause unintended exceptional intestinal gas
production, which may induce critical prostate migration
in prostate cancer external beam radiotherapy. Thus,
patients with DM receiving pelvic radiotherapy should
be asked whether they are taking an AGI prior to radio-
therapy, and they should discontinue use of that particular
medicine before beginning radiotherapy.
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